Id http://purl.obolibrary.org/obo/NCIT_C153116
http://purl.obolibrary.org/obo/NCIT_C153116
Preferred Name

TrkA Inhibitor VMD-928

Definitions
An orally bioavailable, selective inhibitor of tropomyosin receptor kinase A (TrkA; neurotrophic tyrosine receptor kinase (NTRK) type 1; NTRK1; TRK1-transforming tyrosine kinase protein), with potential antineoplastic activity. Upon oral administration, VMD-928 specifically targets and binds to TrkA, inhibits neurotrophin-TrkA interaction and prevents TrkA activation. This prevents the activation of downstream signaling pathways and inhibits cell growth in tumors that overexpress TrkA. Uncontrolled TrkA signaling plays an important role in tumor cell growth, survival, invasion and treatment resistance.
Type http://www.w3.org/2002/07/owl#Class
Delete Subject Author Type Created
No notes to display